Table 1 Clinical characteristics of primary Sjogren’s syndrome patients
Patients | Controls | |
|---|---|---|
(n = 52) (100%) | (n = 52) (100%) | |
Age (years) | 47.36 ± 12.45 | 49.09 ± 11.48 |
Sex (female) | 49 (94.23%) | 48 (92.31%) |
Duration of disease (years) | 4.53 ± 4.64 | NA |
Education (years) | 9.32 ± 4.91 | 11.05 ± 5.37 |
Smoking | 0 | 0 |
Objective ocular involvement | 45 (86.54%) | |
Objective oral involvement | 40 (76.92%) | |
Positive salivary gland biopsy | 39 (75%) | |
ESR (mm after 1 h) | 34.38 ± 21.39 | |
CRP (mg/L) | 11.95 ± 10.36 | |
ANA | 43 (82.69%) | |
Anti-SSA antibody | 41 (78.84%) | |
Anti-SSB antibody | 15 (28.85%) | |
RF | 13 (25%) | |
Current treatment | ||
Corticosteroids | 40 (76.92%) | |
Hydroxychloroquine | 32 (61.54%) | |
Cyclophosphamide | 10 (19.23%) | |
Cyclosporine | 12 (23.07%) | |
Methotrexate | 2 (3.85%) | |
Mycophenolate mofetil | 4 (7.69%) | |
Tripterygium wilfordii | 6 (11.54%) | |
Other immunosuppressant agent | 2 (3.85%) | |
Disease activity indexes | ||
ESSPRI | 3.14 ± 1.63 | |
ESSDRI | 9.17 ± 6.08 | |